New radioactive dye could sharpen heart scans
NCT ID NCT04528758
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This early study tests a new radioactive dye, F-18 rhodamine 6G, to see if it can produce clearer PET scans of the heart. The dye is injected and then images are taken to measure blood flow in the heart muscle. The trial includes both healthy volunteers and people with stable coronary artery disease. The goal is to evaluate image quality and whether the dye can accurately show blood flow in small and large heart vessels.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a radioactive form of rhodamine 6G called F-18 rhodamine 6G, used as a PET imaging dye
- What this could lead to
- If successful, this imaging method could provide clearer, more detailed heart scans to help doctors assess coronary artery disease and blood flow in both small and large heart vessels.
- What could go wrong
- This is a very early, small study (15 people) focused on image quality and safety, not on treating disease. The dye may not prove better than existing methods, and its use is limited to imaging, not therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
15 people
The number who actually took part.
- Started
-
Oct 2018
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male and female, 21-75 years of age and any race. * Capable of giving written informed consent. * "Healthy adult volunteer subject" is someone who is volunteering to undergo imaging procedures and based on screening procedures has no known significant health problems. * Stable patients with known or suspected coronary artery disease that are scheduled to have or have undergone a clinically indicated conventional rest/stress SPECT MPI and no intervention between SPECT and PET. * Female subjects must not be pregnant or lactating. Exclusion Criteria: * Has any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the subject, limit the subject's ability to tolerate the research procedures, or interfere with collection of the data. * Have abnormal findings on any screening/baseline procedure, e.g. physical examination, laboratory tests, electrocardiogram that suggest the subject might have a condition that could, in the opinion of the Sponsor-Investigator, affect the subject's response to the radiopharmaceutical or related research procedures. * Is deemed likely to be unable to perform all research procedures for any reason, (e.g., subjects unable to lie still or inability to tolerate up to 60 minutes in a supine position with arms up during the PET imaging procedures due to chronic back/shoulder pain or arthritis as assessed by physical examination and medical history). * Has a history of hypersensitivity to Fluorine-18 or other radiopharmaceutical or any of its excipients. * Have contraindications to cardiovascular PET/CT imaging such as claustrophobia. * Have high blood pressure (\>200/110) * Have Epilepsy * Have major kidney or liver problems * Have current or past history of major medical illness * Currently using recreational drugs * Body weight of \> 300 lbs. (weight limit of the PET/CT table) * Stable Cardiac Disease: Rest/Stress Group only: * Cardiac patients who suffer an intervening clinical event such as worsening angina pectoris or myocardial infarction or whom undergo a myocardial revascularization procedure or have myocardial ischemia at rest. * Sinus node disease (e.g. SA block) or symptomatic bradycardia, second or third degree atrioventricular (AV) block. * Pre-existing obstructive lung disease (e.g. asthma) that precludes the safe administration of the pharmacological stressor according to the approved label. * Uncontrolled and severe hypertension (e.g. systolic blood pressure \>200 mmHg, diastolic blood pressure \>110 mmHg). * Baseline hypotension (e.g. systolic blood pressure \< 90 mmHg, diastolic blood pressure \<50 mmHg). * Seizures * The use of caffeine, nicotine or over the counter cold medicines within 12 hours prior to stress imaging day with regadenoson. * The theophylline-based medications or dipyridamole within 48 hours prior to each imaging day.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- SMART-I: SiroMax™ Multi-Center coronary artery lesion treatment - safety and feasibility study of SiroMax SCB in ISR and DNSV
- Hospital-to-Home transitional cardiac rehabilitation as a transition from Centre-Based cardiac rehabilitation after cardiac surgery: a Single-Blind randomised controlled trial
- Opportunistic screening of coronary artery calcium on Non-Gated routine chest CT using artificial intelligence: retrospective external validation and clinical risk stratification
- AI heart scan software aims to spot dangerous blockages without invasive probes
- A shot of nicorandil before stenting might keep blood flowing
- Can personalized breathing settings protect lungs during heart surgery?